CareLit · DOI-Nachweis · Aktuelle Neurologie
The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US
DOI 10.1055/s-0029-1238714
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Brennan, B Nagy, A Brandtmüller, SK Thomas, M Gallagher, SD Sullivan, R Akehurst
ZeitschriftAktuelle Neurologie
Ausgabe10/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
A novel rivastigmine transdermal patch has recently been approved in the US for the treatment of Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). The current objective was to model the incremental cost-utility of the rivastigmine patch versus best supportive care (BSC; no active treatment) in the management of AD, from the perspective of a US payer. The incremental costs and number of institutional d…
Zitieren
Zitierempfehlung
A Brennan, B Nagy, A Brandtmüller, SK Thomas, M Gallagher, SD Sullivan, R Akehurst (2009) The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US. Aktuelle Neurologie (10). https://doi.org/10.1055/s-0029-1238714
Mit CareLit weiterarbeiten